BRUSSELS, BELGIUM -- (Marketwire) -- 11/20/08 --

Preliminary Top Line Results of Phase III Trial Show Significant Decreases in Pain and Fatigue and Improved Daily Function in Fibromyalgia Patients

PALO ALTO, CA/USA and BRUSSELS, Belgium, November 20, 2008 at 10:00 PM (CET) - press release, regulated information - Jazz Pharmaceuticals, Inc. (Nasdaq: JAZZ) and UCB (Euronext Brussels: UCB) announced today positive preliminary top-line results from the first of two Phase III clinical trials of sodium oxybate (JZP-6) for the treatment of fibromyalgia. The randomized, double-blind, placebo-controlled study achieved its key endpoints, demonstrating that sodium oxybate significantly decreased pain and fatigue, and improved daily function in patients with fibromyalgia.

"There is a significant unmet need in diagnosing and treating millions of patients with fibromyalgia. Potential new treatments that address the various symptoms can have a significant impact on patients' quality of life," said I. Jon Russell, M.D., Ph.D., one of the study's lead investigators and Associate Professor of Medicine, Division of Clinical Immunology and Rheumatology, and Director, University Clinical Research Center, University of Texas Health Science Center at San Antonio.

The 14-week placebo-controlled study included 548 adult patients with fibromyalgia randomized to one of three treatment arms: sodium oxybate 4.5 g/night, sodium oxybate 6 g/night or placebo. The primary outcome measure, viewed by both U.S. and EU regulatory authorities as a clinically meaningful endpoint, was the proportion of patients who achieved at least 30 percent reduction in pain from baseline to endpoint based on the Pain Visual Analog Scale (VAS). In the EU, it is also considered that the Fibromyalgia Impact Questionnaire (FIQ) data is equally relevant. FIQ data are considered supportive data by U.S. regulators.

In the top-line results, significantly more patients treated with sodium oxybate achieved 30 percent or greater improvement in their pain compared with placebo. Of those patients receiving sodium oxybate treatment, 46.2 percent of patients on 4.5 g/night and 39.3 percent of patients on 6 g/night reported this level of pain relief (VAS), compared with 27.3 percent of patients on placebo. These results were highly statistically significant.

Patients' physical functioning and ability to perform daily tasks, as measured by the FIQ, were significantly different from placebo for the 4.5 g/night dose and approached significance for the 6 g/night dose.

Patients receiving sodium oxybate also reported significant improvement in fatigue, another common symptom of fibromyalgia, at both active dosage levels.

Adverse events were similar to those seen in other clinical studies of sodium oxybate. The most common adverse events (greater than or equal to 5 percent and occurring at twice the rate of placebo) were headache, nausea, dizziness, vomiting, diarrhea, anxiety, and sinusitis. Sodium oxybate was generally well tolerated, with the majority of adverse events reported being mild to moderate in nature.

"Achieving positive sodium oxybate data in fibromyalgia from this Phase III clinical trial is an exciting milestone for Jazz Pharmaceuticals and it supports our commitment to improving care for patients with serious psychiatric and neurological conditions," said Samuel Saks, M.D., Chief Executive Officer of Jazz Pharmaceuticals.

"As UCB continues to focus on serious diseases of the central nervous system and immunology, we are delighted to partner with Jazz Pharmaceuticals in bringing new hope for patients with this under-treated condition", said Roch Doliveux, Chief Executive Officer of UCB.

Only primary efficacy and safety data have been reviewed at this time. Further analyses will be undertaken to examine the full results, including secondary endpoints, in greater detail.